Optimus Announces Interim Clinical Results from Phase III Clinical Trials of Molnupiravir Conducted in India

Hyderabad (Telangana) [India], July 21: Optimus Pharma on Sunday submitted the interim result of Phase III Clinical Trials for orally administered Molnupiravir capsules on patients with Mild Covid-19 patients. With an acute shortage of antiviral drugs in the market against the SARS-CoV-2 infection, it is imperative that more drugs with potent antiviral activity against SARS-CoV-2 be introduced.

In a statement, the MD and Chairman Dr. D Srinivasa Reddy had declared that Optimus pharma has internally developed the active pharmaceutical ingredient (API) and the formulations for the product and had obtained approval for conducting Phase 3 Clinical Trial.

As per the clinical trial protocol approved, 1218 subjects with mild COVID-19 will be randomised in the study in a 1:1 ratio to Molnupiravir with the standard of care, or standard of care alone. The treatment duration is a maximum of 05 days and the total study duration will be a maximum of 28 days from randomisation.

“Optimus is all geared to immediately begin manufacturing of Molnupiravir for COVID-19 patients in India. The interim results on 353 patients have shown promising results of Molnupiravir. The drug has been successful in reducing viral load effectively with RT-PCR negativity achieved 78.3 % in the test arm compared to 48.4% in the standard of care arm on Day 5. Day 10 and Day 14 of the treatment duration have also given excellent results wherein the remaining patients have successfully achieved RT-PCR negativity. The trial has also revealed clinical improvement in a significantly high proportion of patient’s health. The safety of the drug has also been established with no observed side effects, co-morbidity, or morbidity observed during and after the treatment duration,” Chairman & Managing Director – Dr. D Srinivasa Reddy said.

Optimus has approached the Drugs Controller General of India (DCGI) to seek Emergency Use Authorization for Molnupiravir in India.

Optimus Pharma is committed to serve the nation and fight back the pandemic to restore normalcy in the lives of people affected by COVID-19 at the earliest. With the cooperation of the government and our stakeholders, and a special thanks to the Subject Expert Committee of the CDSCO for their valuable contribution and their recommendations to the project, we hope to deliver the product in India by leveraging our solid distribution strength across the country.

Leave a Reply

Your email address will not be published. Required fields are marked *

National

Energy Beverages Celebrated World Environment Day With Tree Plantation Drive

The initiative by the makers of CLEAR premium water reflects their commitment towards the environment  Ahmedabad (Gujarat) [India], June 06: Energy Beverages Private Limited, an innovative beverage company known for CLEAR premium water and its commitment to delivering superior quality and exceptional value to customers, celebrated World Environment Day on June 5 by undertaking a […]

Read More
National

KP Group’s Faruk Patel: Championing a better environment for future generations

Surat (Gujarat) [India], June 6: Founded by Faruk G Patel in 1994, KP Group has emerged as a formidable player in the field of renewable energy with a proven track record of executing both wind and solar energy projects. From humble beginnings, the group now comprises 35 companies, of which two are listed on the […]

Read More
National

World Environment Day Celebrated at IDT: Inspiring the Next Generation through Earth Colors and Natural Dye Methods

Surat (Gujarat) [India], June 6:  IDT (Institute of Design and Technology), in collaboration with Archroma, celebrated World Environment Day with a captivating workshop to educate and inspire students about the beauty of Earth colors and the importance of sustainable fashion. The event, held at IDT’s premises, witnessed the enthusiastic participation of students eager to learn […]

Read More